FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Abstract Full Text

Article: NEJM -- Martinez E et al. Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection. N Engl J Med 2003;349(11):1036-46.

View Figure Supplementary Appendix 1. Median CD4 Cell Counts during the Study. There were no significant differences among the groups at any point (P>0.40 by the Kruskal–Wallis test). Bars represent interquartile ranges.

View Figure Supplementary Appendix 2. Proportion of Patients with Plasma Triglyceride Levels above 400 mg per Deciliter (4.5 mmol per Liter) (Panel A) and Total Cholesterol Levels above 240 mg per Deciliter (6.2 mmol per Liter) (Panel B). In Panel A, Fisher’s exact test revealed the following P values: P=0.39 at 3 months, P=0.66 at 6 months, P=0.07 at 9 months, and P=0.05 at 12 months. In Panel B, Fisher’s exact test revealed the following P values: P<0.001 at 3 months, P=0.09 at 6 months, P=0.005 at 9 months, and P<0.001 at 12 months. The numbers below the graphs are the numbers of patients for whom data were available.

View Figure Supplementary Appendix 3. Proportion of Patients with Moderate or Severe Lipoaccumulation (Panel A) and Moderate or Severe Lipoatrophy (Panel B). There were no significant differences among the groups at any point (P>0.50 by the chi-square test).